A new study showed that enough often two certain genetic variations of fallen into depression people awakens thoughts about suicide during treatment by conventional antidepressants.
During the experiment reports of suicidal thoughts came from 2 to 15 times more often from patients subjected to treatment of antidepressants with key gene variations than patients without them, said psychiatrist Gonzalo Laje from National Institute of Mental Health in Bethesda. Probationers received citalopram, usually issued antidepressant that is related to drugs of fluoxetine type (Prozac).
These results should be taken into account in medicine before invent of genetic test for identifying people liable to risk of suicidal thoughts in treatment of antidepressants.
The study found two critical gene, which influence the formation of cell receptors, reacting to glutamate (regulates metabolism in tissues, affects the electrical conductivity of pulses), which is involved in the antidepressant effect. Variations of these genes provoke suicidal thinking only of oppressed people receiving antidepressant, researchers have concluded in the American Journal of Psychiatry for October.
Laje’s team studied 1915 patients, collected from all over the country for study that was federal level-funded. Probationers received standard doses of citalopram during 14 weeks. Researchers took blood samples of patients and studied the changes in the genetic code by 768 stations of 68 genes that may exacerbate the depression.
Combination of different versions of the gene in 120 participants, who have thought about suicide during the test, the researchers compared with DNA samples from those participants who have not thought about suicide. Previous experiments have shown that 4 percent of people receiving antidepressant is beginning to think about suicide.
People usually inherit two copies of each gene, one from each parent. Some have two versions of the same gene, while others have a pair of identical genes.
Progression of thoughts about suicide was occured in 1 percent of patients who have inherited at least one copy of the first gene variant, bearing information about glutamate, with or without a copy of the second variant of this gene. Roughly a one third of these individuals frequently appeared thought about suicide.
Approximately 41 percent of the participants had one or two different copies of a second gene with information about glutamate, but neither one of the first. Only in one-fifth of these individuals thoughts about death and suicide are developed.
Most participants - 58 percent - did not have any version of the gene investigated. Less than 5 percent of these individuals reported suicidal thoughts during treatment.
Later the team of Laje reported on two additional versions of a gene associated with thoughts about suicide in patients taking antidepressant.
Further study may help create a genetic test on the likelihood of success of antidepressant treatment, , Weissman said. Only 25 percent of patients in the study of Laje, who thought about suicide, recovering from depression when taking medication, and 42 percent of those who had no such thoughts.
Recent Comments